VRTX - Vertex Pharmaceuticals
$396.55 -3.68 (-0.92%)
Updated: 03:13 May 5, 2024 ESTNext Hour's AI Forecast
98.43%
Avg. Accuracy (AI)
$415.52
Next Session's AI Forecast
96.85%
Avg. Accuracy (AI)
$191.85
Next Week's AI Forecast
N/A
Trend's Accuracy (AI)
N/A
| Rank (0-100) |
| Rank (0-100) |
| Curr. Week | Curr. Month | Curr. Quarter | Next Quarter | Curr Year | 1.45 | 0.26 | -0.02 | 0.09 | 0.08 |
|---|
CURRENT VOLATILITY RANK
Variation from the lowest to the highest value in a period.
| Curr. Week | Curr. Month | Curr. Quarter | Next Quarter | Curr Year | 1.45 | 0.82 | 0.84 | 1.02 | 0.99 |
|---|
STOCHASTIC METRIC
The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.
| Curr. Week | Next Week | Curr. Month | Curr. Quarter | 100% | 100% | 100% | 64.37% |
|---|
MOVING AVERAGE METRIC
| 5 Sessions | Change 5 Sessions | 20 Sessions | Change 20 Sessions | 50 Sessions | Change 50 Sessions | 200 Sessions | 416.02 | 3.2% | 403.12 | -0.26% | 404.19 | 0.66% | 401.54 |
|---|
RSI METRIC
| RS Hour | RSI Hour | RS Day | RSI Day | 0.37 | 69.23 | 2.74 | 27.01 |
|---|
Vertex Pharmaceuticals Technical Analysis News
Mentions in the news over the last three days
In the last three days Vertex Pharmaceuticals was mentioned 1 times in 1 different publications.
Vertex (VRTX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
"For the quarter ended March 2024, Vertex Pharmaceuticals (VRTX Quick QuoteVRTX - Free Report) reported revenue of $2.69 billion, up 13.3% over the same period last year. EPS came in at $4.76, compared to $3.05 in the year-ago quarter."
At May 8, 2024, 1:30 pm
Zacks
Vertex Pharmaceuticals
50 Northern Avenue
Boston, MA 02210
United States
617 341 6100
https://www.vrtx.com
| Sectors: | Healthcare |
| Industry: | Biotechnology |
| F. Time Employees: | 5400 |
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Corporate Governance
Vertex Pharmaceuticals Incorporated’s ISS Governance QualityScore as of May 1, 2024 is 8. The pillar scores are Audit: 9; Board: 6; Shareholder Rights: 6; Compensation: 8.
List of holders with stock participation in Vertex Pharmaceuticals.
| Holder Rank | Holder | Shares | Date Reported | % Out | Value |
|---|